News for Kodiak Sciences Inc. (KOD)

Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Read why KOD stock is a Buy.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Tuesday. Shares of Polaris Inc. PII fell sharply in today's pre...

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

PR NewswirePALO ALTO, Calif., Jan. 7, 2025 PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 300 points on Thursday. The Dow traded down 0.79% to 42,208.88 while ...

Shares of Rumble Inc.

CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (Nasdaq: KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice® fully human antibody platform.

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday. Shares of Pactiv Evergreen Inc. PTVE rose sharply during Monday's sessio...

Shares of Kodiak Sciences (KOD) rallied 32% Monday after Jefferies upgraded the stock to buy from hold, citing the company’s turnaround and upcoming catalysts. Read more here.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Kodiak Sciences to Present at Innovate Retina 2024

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are...

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow t...

The increasing number of diagnosed cases of wet AMD, the current therapies, and the launch of emerging therapies will drive the wet AMD market growth in...

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET)..